British Patient Capital is providing an update on its Future Fund program. The entity reports that funds dedicated to early-stage “deeptech” and “life sciences companies” stating that it has invested £111.4 million into 16 companies, alongside £724 million of third-party capital investment since August 2023.
Ian Connatty, Managing Director, Direct and co-investment, of British Patient Capital, says that growth-stage firms require more time and money to reach their potential, and British Patient Capital is addressing this need.
“There is more to do, but we are proud to see the tangible impact of the program so far and remain committed to investing in the leading companies of tomorrow.”
In response the the experience so far, British Patient Capital is reducing the minimum size of the funding from £30 million to £20 million and sponsor investors may now include corporate venture capital funds which have a carry or Long-Term Incentive Plan structure in place.
The Process Evaluation and Early Impact Assessment was undertaken by Ipsos UK claiming there was potential to be more catalytic in leading new equity funding rounds and expanding the ecosystem of potential investments.
